Articles tagged with: Smoldering Multiple Myeloma
The International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple myeloma.
The criteria have been published in The Lancet Oncology and are accompanied by recommendations for monitoring and updated criteria for other related plasma cell disorders.
The new diagnostic criteria represent a paradigm shift in the approach to multiple myeloma and will have considerable impact on the management of the disease.
For decades, the diagnosis of multiple myeloma required the presence of “end-organ” damage that could be attributed to the underlying plasma cell disorder. Thus, …
A recently published Greek study provides updated data on the significance of MRI-detected focal lesions in the spine in patients with smoldering myeloma.
The Greek study confirms that having more than one focal lesion in the spine puts a smoldering myeloma patient at a noticeably higher risk of progressing to multiple myeloma.
Focal lesions are areas of abnormal cells in the bone marrow. They are not lesions in the outer (hard) area of the bone – lesions which are often called “lytic” lesions.
The Greek researchers found that the smoldering …
The sun is shining, and our cats are dreaming in sunbeams about catching quick-footed squirrels just out of reach. Summer … It feels good to finally be here, and so it’s fitting that I now conclude the three-part series on our journey from the dark days of my husband Daniel’s initial diagnosis to the brighter days of the present.
As I mentioned in my last column, we moved to Houston in 2012 so that Daniel could be treated by a myeloma specialist at the MD Anderson Cancer Center. I truly …
This year’s American Society of Clinical Oncology (ASCO) annual meeting in Chicago ended last Tuesday.
The day before the meeting ended was the busiest day at the meeting with regard to myeloma research. It featured a session of oral presentations in the morning and a poster session in the afternoon. In addition, an education session was held in the afternoon that included one myeloma-related talk, given by Dr. Leif Bergsagel of the Mayo Clinic, about progress in the treatment of multiple myeloma (article in the ASCO 2014 Educational Book). …
After my husband Daniel’s initial diagnosis with monoclonal gammopathy of undetermined significance (MGUS) in 2012, I couldn’t shake the feeling that the “treatment” plan of watching and waiting, which had been suggested by a local hematologist/oncologist, was not enough.
The hematologist/oncologist wasn’t a myeloma specialist, and he wasn’t connected to a research hospital. My mother had ovarian center in the 1990s, and I know what an impact it had on her recovery to have had a research hospital involved in her treatment.
I believed that we couldn’t get the …